The National TB Controllers Association’s (NTCA) released a new resource for providers who are considering using the isoniazid-rifapentine (3HP) regimen to treat latent Mycobacterium tuberculosis infection (LTBI). It is based on the Centers for Disease Control and Prevention’s (CDC) recently released guidance in the article Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection, MMWR, June 29, 2018;67(25):723–726.

The NTCA created Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI) primarily for private provider partners to supplement the CDC's guidance. However, this NTCA provider guidance contains essential information for all providers treating LTBI including providers in the TB public health community.

Developed from current best practices and evidence-based knowledge in use by several of our member programs across the United States, Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI) was designed to help clinical providers and nursing managers

• Quickly identify and answer key questions when considering whether to start a patient on the 3HP regimen
• Assess the appropriateness of self-administered therapy of 3HP for each individual patient
• Ensure that the correct drugs for the 3HP regimen are prescribed and provided to the patient
• Handle questions on side effects and adverse reactions for a patient currently on the 3HP regimen

Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI) is available in PDF format:  Download